The Adult Respiratory Distress Syndrome (ARDS) continues to be a major cause of morbidity and mortality in the United States and its most common cause is sepsis syndrome. There is reason to believe that tumor necrosis factor alpha (TNFalpha) and other cytokines are directly involved in oxidant stress. Depletion of glutathione in these closely related syndromes may be a fundamental process in their development. TNFalpha has been implicated as a major mediator of lung injury following sepsis and anti-TNF has been successful in preventing pathophysiologic changes and death in animal models of bacterial and endotoxemia shock. In the current studies, we propose to use an ovine polyclonal Fab purified antibody to TNF to study patients with early ARDS who will be randomized to receive either placebo or glutathione therapy in order to increase glutathione concentrations in red cells, plasma and alveolar lining fluid in order to increase glutathione reserve and hence resistance to oxidant stress. Employing both trials as tools, we will explore the relevance of TNFalpha and glutathione to other specimens from patients enrolled in these studies, we will examine the development of lung inflammation in sepsis and its progress and resolution in ARDS. In addition to the biochemical parameters, the results of these studies will be used to determine the feasibility of using these approaches in the therapy of sepsis and ARDS.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL019153-20
Application #
5213246
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
20
Fiscal Year
1996
Total Cost
Indirect Cost
Brigham, K L; Lane, K B; Meyrick, B et al. (2000) Transfection of nasal mucosa with a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: comparison with protein therapy. Hum Gene Ther 11:1023-32
Conner, B D; Bernard, G R (2000) Acute respiratory distress syndrome. Potential pharmacologic interventions. Clin Chest Med 21:563-87
Mangialardi, R J; Martin, G S; Bernard, G R et al. (2000) Hypoproteinemia predicts acute respiratory distress syndrome development, weight gain, and death in patients with sepsis. Ibuprofen in Sepsis Study Group. Crit Care Med 28:3137-45
Brigham, K L; Stecenko, A A (2000) Gene therapy for acute lung injury. Intensive Care Med 26 Suppl 1:S119-23
Arons, M M; Wheeler, A P; Bernard, G R et al. (1999) Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group. Crit Care Med 27:699-707
Peters, M T; Brigham, K L; King, G A et al. (1999) Optimization of cationic liposome-mediated gene transfer to human bronchial epithelial cells expressing wild-type or abnormal cystic fibrosis transmembrane conductance regulator (CFTR). Exp Lung Res 25:183-97
Wheeler, A P; Bernard, G R (1999) Treating patients with severe sepsis. N Engl J Med 340:207-14
Snapper, J R; Trochtenberg, D S; Hwang, Y S et al. (1999) Effect of pulmonary edema on tracheal diameter. Respiration 66:522-7
Dupont, W D; Plummer Jr, W D (1998) Power and sample size calculations for studies involving linear regression. Control Clin Trials 19:589-601
Clark, M P; Chow, C W; Rinaldo, J E et al. (1998) Multiple domains for initiator binding proteins TFII-I and YY-1 are present in the initiator and upstream regions of the rat XDH/XO TATA-less promoter. Nucleic Acids Res 26:2813-20

Showing the most recent 10 out of 202 publications